

Supplemental material 3. Clinical characteristics of the subjects without using insulin secretagogues

Clinical parameter	All subjects	< 65 years old	≥ 65 years old
Number (male/female)	276 (152/115)	158 (89/69)	109 (63/46)
Age (years old)	58.8 ± 14.8	49.2 ± 11.1	72.8 ± 4.8
BMI (kg/m ²)	25.9 ± 5.5	27.4 ± 5.7	23.9 ± 4.3
Duration of diabetes (years)	10.8 ± 8.8	7.9 ± 7.5	15.0 ± 8.9
Medication			
Metformin	96 (25.8 %)	59 (28.1 %)	37 (22.8 %)
Thiazolidinediones	68 (18.3 %)	37 (17.6 %)	31 (19.1 %)
Sulfonylurea	104 (28.0 %)	51 (24.3 %)	53 (52.7 %)
Glinide	32 (8.6%)	15 (7.1 %)	17 (10.5 %)
DPP-4 inhibitors	4 (1.1 %)	2 (1.0 %)	2 (1.2 %)
Alpha-glucosidases inhibitor	63 (16.9 %)	27 (12.9 %)	36 (22.2 %)
HbA1c (%)	9.5 ± 2.0	9.9 ± 2.1	9.0 ± 1.7
Glycoalbumin (%)	26.7 ± 7.7	26.6 ± 8.4	26.8 ± 6.5
Fasting plasma glucose (mg/dL)	175.9 ± 67.9	180.0 ± 62.2	170.6 ± 75.3
GA/HbA1c ratio	2.81 ± 0.51	2.70 ± 0.50	2.99 ± 0.48
HOMA-%β	46.2 ± 40.8	49.2 ± 43.2	41.8 ± 37.0
Systolic blood pressure (mmHg)	129.8 ± 15.8	130.9 ± 17.1	128.2 ± 13.6
Diastolic blood pressure (mmHg)	72.2 ± 9.5	73.5 ± 9.7	70.4 ± 8.9
Total cholesterol (mg/dL)	199.7 ± 40.3	202.9 ± 40.1	195.0 ± 40.3
LDL cholesterol (mg/dL)	121.7 ± 35.0	125.5 ± 34.7	116.4 ± 35.0
HDL cholesterol (mg/dL)	51.2 ± 17.8	47.8 ± 16.3	56.3 ± 18.9
Triglyceride (mg/dL)	137.0 ± 73.6	151.4 ± 78.9	116.8 ± 60.1
Apolipoprotein B (mg/dL)	99.6 ± 26.6	105.0 ± 26.6	91.8 ± 24.9
Apolipoprotein E (mg/dL)	4.54 ± 3.47	4.38 ± 1.15	4.79 ± 5.27
Creatinine (mg/dL)	0.74 ± 0.25	0.68 ± 0.20	0.83 ± 0.27
BUN (mg/dL)	17.0 ± 7.6	14.9 ± 4.6	20.0 ± 9.8
CRP (mg/dL)	0.56 ± 1.43	0.61 ± 1.61	0.49 ± 1.14
Urinary albumin (mg/gCre)	42.1 ± 86.8	47.4 ± 106.7	35.4 ± 50.1

Abbreviations: BMI, body mass index; GA, glycoalbumin; HOMA, homeostasis model assessment; LDL, Low-density lipoprotein; **DPP-4, Dipeptidyl-peptidase-4;**
HDL, high-density lipoprotein; CRP, C-reactive protein. Data are shown as mean \pm SD.